Name: GHK-Cu
Brand: PeptidesDirect
SKU: PD-GHKCU-50MG
Availability: InStock

Question 1

What is GHK-Cu?

Accepted Answer

GHK-Cu is a naturally occurring copper peptide composed of three amino acids (glycyl-histidyl-lysine) that complexes a divalent copper ion. It is studied in preclinical research in the context of wound healing, collagen stimulation, antioxidant responses and skin-regeneration models.

Question 2

How is GHK-Cu typically used in research?

Accepted Answer

In preclinical models, GHK-Cu is investigated both topically and subcutaneously. Topical applications target skin-regeneration and collagen research, while subcutaneous protocols address systemic models such as tissue repair or skin-quality markers. Specific dosing varies by study design and should be taken from the respective publications.

Question 3

How do I store GHK-Cu after reconstitution?

Accepted Answer

Store lyophilised GHK-Cu protected from light at -20 °C. After reconstitution with bacteriostatic water, storage at 2-8 °C is recommended, also protected from light, since the copper-peptide complex is sensitive to oxidation and UV. Avoid repeated freeze-thaw cycles.

Question 4

What quality control backs your GHK-Cu?

Accepted Answer

Every batch of GHK-Cu ships with a certificate of analysis from Janoshik Analytical, an independent third-party laboratory, at a minimum purity of 98%. We do not run a lab ourselves: the manufacturer commissions this test, and we pass the report on unchanged, with an online verification link on the product page. This batch also carries a second, independent test from Kovera Labs, commissioned outside the manufacturer.

Question 5

How does GHK-Cu actually work at the cellular level, according to the published research?

Accepted Answer

GHK-Cu is studied as a signaling tripeptide-copper complex that stimulated collagen synthesis in cultured human skin fibroblasts starting at picomolar concentrations (10^-12 to 10^-11 M) and peaking at 1 nanomolar (10^-9 M), an effect independent of any increase in cell number, meaning it drove more collagen output per cell rather than more cells (Maquart FX et al., FEBS Lett 1988, PMID 3169264). In irradiated human dermal fibroblasts, 1 nM GHK-Cu in culture also restored a near-normal population doubling rate and increased basic FGF and VEGF output early after exposure (Pollard JD et al., Arch Facial Plast Surg 2005, PMID 15655171). Separately, ex vivo human cadaver skin studies tracked the copper component itself moving through skin layers: 136.2 µg/cm² permeated dermatomed skin over 48 hours and 82 µg/cm² was retained in the tissue as a depot (Hostynek JJ et al., Inflamm Res 2010, PMID 20703511). All of this mechanistic evidence comes from cell culture or isolated cadaver skin, not a living human body, so it describes what GHK-Cu does to cells and tissue in a dish, not what happens after a person uses it.

Question 6

What has GHK-Cu actually been tested on, in what models and species?

Accepted Answer

GHK-Cu has been studied almost entirely in cell culture and animals, across models that do not share a single indication. Its wound-healing evidence includes a mouse thermal-scald model, where a liposomal GHK-Cu formulation increased HUVEC proliferation by about 33% and produced full wound closure by day 14 (Wang X et al., Wound Repair Regen 2017, PMID 28370978), and a mouse cigarette-smoke emphysema model, where daily intraperitoneal GHK-Cu reduced lung inflammation and oxidative-stress markers over 12 weeks (Zhang Q et al., Front Mol Biosci 2022, PMID 35936787). It has also been tested in human dermal fibroblast cultures and ex vivo human cadaver skin (see the mechanism question). Not every model showed a benefit: a rat irradiated skin-flap study found topical GHK-Cu gel gave no improvement in blood vessel count or VEGF and a significantly larger ischemic area than the control ointment (Parker NP et al., Otolaryngol Head Neck Surg 2013, PMID 23744835).

Question 7

What dose of GHK-Cu was used in the studies, and is there a published human dose?

Accepted Answer

In Zhang Q et al. (Front Mol Biosci 2022, PMID 35936787), mice with cigarette-smoke-induced emphysema received GHK-Cu at 0.2, 2, or 20 mg per kg per day, by intraperitoneal injection, on alternate days, for 12 weeks of smoke exposure. That is what the study administered, in an unrelated lung-disease model, not a skin or wound protocol. The skin and wound-healing studies did not use a per-kilogram dose at all: they used molar concentrations in cell culture (around 1 nanomolar) or a topical percentage on isolated cadaver skin (0.68% copper), neither of which converts to a body-weight dose. No human dosing protocol has been published for GHK-Cu; the one registered human trial (ClinicalTrials.gov NCT07437586, a Phase 2 topical wound-healing study) is still recruiting and has not reported a dose-finding result.

Question 8

What did the GHK-Cu studies actually find, and how fast did the effect show up?

Accepted Answer

Outcomes vary by model and none were measured in humans. In the fibroblast studies, irradiated cells treated with 1 nM GHK-Cu showed a faster population doubling time and higher bFGF and VEGF output detected early after exposure, with no exact percentage given in the abstract (Pollard JD et al., Arch Facial Plast Surg 2005, PMID 15655171). In the mouse scald-wound model, GHK-Cu-liposomes produced full wound closure by day 14 post-injury (Wang X et al., Wound Repair Regen 2017, PMID 28370978), and in the 12-week mouse emphysema protocol, GHK-Cu reduced inflammatory cytokines and restored antioxidant balance over the full course rather than showing an early readout (Zhang Q et al., Front Mol Biosci 2022, PMID 35936787). One study found the opposite of a benefit: after 10 days of twice-daily topical GHK-Cu gel, irradiated rat skin flaps had a significantly larger ischemic area than controls, 5.0 cm² versus 3.8 cm² (P=0.011) (Parker NP et al., Otolaryngol Head Neck Surg 2013, PMID 23744835).

Question 9

What side effects has GHK-Cu shown in studies?

Accepted Answer

None of the six studies behind our research page (in vitro fibroblast work, ex vivo cadaver skin, mouse emphysema, mouse scald wound, rat irradiated flap) reported an adverse event in the clinical sense, because none of them was a human safety study designed to monitor one. The one number that does look like a safety signal comes from Parker NP et al. (Otolaryngol Head Neck Surg 2013, PMID 23744835): rats treated with topical GHK-Cu gel for 10 days after irradiation developed a significantly larger ischemic area in the skin flap than untreated controls, 5.0 cm² versus 3.8 cm² (P=0.011), meaning the treated tissue did worse, not better, on that measure. The mouse studies (Zhang 2022, PMID 35936787; Wang 2017, PMID 28370978) reported no deaths, weight loss, or organ toxicity in their results sections, but neither ran a dedicated toxicology arm. No published rate of any side effect exists for humans, because no completed human trial of GHK-Cu has been published.

Question 10

What is not known about GHK-Cu's safety, i.e. what is the honest evidence gap?

Accepted Answer

There is no published human safety data for GHK-Cu at all: the only registered human study, a Phase 2 topical wound-healing trial (ClinicalTrials.gov NCT07437586), is still recruiting and has posted no results. No dedicated toxicology or repeat-dose safety study for GHK-Cu itself turned up in the sources we reviewed, and a PubMed search for GHK-Cu-specific adverse events, contact dermatitis, or irritation returned no relevant hit. Everything currently known comes from cell culture, ex vivo cadaver skin, and small rodent studies using routes (intraperitoneal, topical) different from any human use, so questions like long-term exposure or systemic copper accumulation are simply unanswered in the literature. Two of the most-cited review articles summarizing GHK-Cu's broader biology (Pickart L et al., Int J Mol Sci 2018, PMID 29986520; Biomed Res Int 2015, PMID 26236730) are narrative reviews whose authors are affiliated with a skin-care research company (Skin Biology, Bellevue WA) with a commercial interest in copper-peptide products, a reason to read their broader claims cautiously rather than as independently established fact.

Question 11

Is GHK-Cu approved by the FDA, EMA, or any regulator?

Accepted Answer

GHK-Cu is not approved by the FDA, EMA, or any other medicines regulator as a drug for any condition. It is, however, a cosmetic ingredient (commonly listed under the INCI name Copper Tripeptide-1) used in topical skincare formulations, a different regulatory category that does not require pre-market drug-efficacy approval. The only registered human clinical study we found, a Phase 2 topical wound-healing trial (ClinicalTrials.gov NCT07437586), is recruiting and has not published results, so there is no completed human trial supporting a medical claim either. Outside that cosmetic-ingredient use, GHK-Cu is sold and studied strictly as a research compound, with no approved therapeutic indication anywhere.

Question 12

How much bacteriostatic water do I need for GHK-Cu, and does the ratio matter for stability?

Accepted Answer

Our GHK-Cu vials (50 mg and 100 mg) follow the same reconstitution approach as our other lyophilized peptides: bacteriostatic water added slowly down the inside wall of the vial, then swirled gently, never shaken, typically 1 to 2 mL per vial. The exact volume sets the resulting concentration in mg per mL, which affects how much liquid corresponds to a given amount for a research measurement, but it does not change the total peptide content of the vial or meaningfully change the chemical stability of the reconstituted solution. What does affect stability is temperature, light exposure, and oxidation of the copper complex, independent of whether 1 mL or 2 mL of water was used. No published stability study compares different water ratios specifically for GHK-Cu, so this is standard peptide-handling practice, not a study finding.

Question 13

How long does reconstituted GHK-Cu last, fridge or freezer?

Accepted Answer

Keep reconstituted GHK-Cu refrigerated at 2 to 8°C, protected from light, and do not freeze the liquid solution, since freezing and thawing a reconstituted peptide solution stresses it more than steady refrigeration does. As practical guidance, consistent with the 2 to 4 week window used for other reconstituted lyophilized peptides in our catalogue, reconstituted GHK-Cu is best used within about 4 weeks. No peer-reviewed stability study has published an exact shelf life for reconstituted GHK-Cu specifically, so this is a conservative handling guideline based on general peptide-storage practice, not a validated study result.

Question 14

What does your GHK-Cu CoA actually show, and how do I verify a specific batch?

Accepted Answer

We currently list four GHK-Cu lab reports. Three are Janoshik Analytical certificates commissioned by the manufacturer: a Blue Cap 100 mg batch at 99.79% purity and 91.34 mg content (tested 25 Nov 2025, verify.janoshik.com/tests/89874_7JSHIUYUC714), a Clear/Silver 50 mg batch at 99.85% purity and 48.35 mg content (same test date, verify.janoshik.com/tests/89872-GHK_CU_50mg_EP4QIRBYZC47), and a Clear/Silver 100 mg batch at 99.45% purity and 114.58 mg content (tested 27 Jan 2026, verify.janoshik.com/tests/102112-Ghk_cu_100_SYH79DCV36D1). The fourth is a community-submitted report, not commissioned by us or the manufacturer: a Purple Cap 50 mg batch tested by Kovera Labs at 99.87% purity and 56.42 mg content (tested 27 Jun 2026, verifiable at koveralabs.com). To check a specific vial, match its cap color and dosage to the batch listed on our /coa page and open the linked verification URL on the testing lab's own site rather than relying on the PDF alone.

Question 15

How does GHK-Cu compare to BPC-157 in mechanism and evidence?

Accepted Answer

BPC-157 and GHK-Cu are both preclinical research peptides studied for tissue repair, but they are structurally and mechanistically unrelated. BPC-157 is a 15-amino-acid fragment derived from a human gastric-juice protein, studied in rat models of tendon-to-bone healing, ligament healing, muscle-tendon junction injury, sciatic nerve injury, and gastric ulcers, with a proposed mechanism centered on angiogenesis and growth-factor signaling. GHK-Cu is a 3-amino-acid peptide bound to copper, occurring naturally in human plasma, studied mainly in skin and wound models (fibroblast cultures, cadaver skin, mouse and rat wound models) with a proposed mechanism centered on stimulating collagen synthesis and growth factors such as VEGF and bFGF in fibroblasts. Both share the same evidence-quality gap: all efficacy data for either peptide is preclinical, with no published human dosing protocol for either, and each now has exactly one registered, not-yet-reported Phase 2 human trial, a topical wound-healing study for GHK-Cu (ClinicalTrials.gov NCT07437586) and a hamstring-strain repair study for BPC-157 (ClinicalTrials.gov NCT07437547).

Question 16

Does GHK-Cu cause breakouts or a purging phase when used topically or in research?

Accepted Answer

None of the published GHK-Cu studies we reviewed (in vitro fibroblast work, ex vivo cadaver skin, or the mouse and rat wound models) measured acne, breakouts, or a purging phase as an outcome, so there is no controlled data confirming or ruling this out. What exists instead is unconfirmed community reporting: some topical copper-peptide users describe temporary skin reactions, including breakouts, in the first one to three weeks, but this has never been studied in a trial, so it cannot be quantified, attributed to a specific concentration, or confirmed as a true GHK-Cu effect rather than a reaction to a formulation's other ingredients. The one published finding that argues against GHK-Cu being harmless on skin is unrelated to acne: a rat study found topical GHK-Cu gel produced a significantly larger ischemic area than a control ointment, 5.0 cm² versus 3.8 cm² (P=0.011) (Parker NP et al., Otolaryngol Head Neck Surg 2013, PMID 23744835). Any report of a purging phase remains anecdotal, not an established, dose-dependent effect.

Question 17

Is cosmetic-grade GHK-Cu the same as research-grade GHK-Cu?

Accepted Answer

Yes, the molecule itself, glycyl-L-histidyl-L-lysine copper(II) complex, is chemically identical regardless of whether a seller markets it as cosmetic grade or research grade. What differs between products sold under those labels is typically the formulation and documentation: a cosmetic serum contains GHK-Cu at a stated percentage alongside preservatives, emulsifiers, and other cosmetic ingredients with cosmetic-industry testing, while a research vial like ours is the unformulated lyophilized peptide alone, sold with a certificate of analysis for identity, purity, and content rather than a cosmetic safety dossier. Neither label changes the underlying peptide-copper structure described in the studies cited above. Our product is sold strictly for laboratory research use, not as a finished cosmetic formulation.

Question 18

What's the difference between GHK and GHK-Cu?

Accepted Answer

Plain GHK is the uncomplexed tripeptide, glycyl-L-histidyl-L-lysine, on its own. GHK-Cu is that same tripeptide bound to a copper(II) ion, forming a distinct metal-peptide complex, and it is this copper-bound form that essentially all of the published research cited above actually used, starting with the original 1988 collagen-synthesis study (Maquart FX et al., FEBS Lett 1988, PMID 3169264) through the 2010 skin-penetration study that specifically tracked the copper component moving through tissue (Hostynek JJ et al., Inflamm Res 2010, PMID 20703511). Because copper delivery and retention in skin is itself one of the measured effects in that research, the two forms are not interchangeable for research purposes. Our product is the copper-bound GHK-Cu, not plain GHK.

Question 19

Does the copper in GHK-Cu change how it should be stored compared to other peptides?

Accepted Answer

Yes. The bound copper ion makes GHK-Cu a redox-active complex, more prone to oxidative degradation from light and air exposure than a peptide with no metal center, such as BPC-157 or TB-500, which is why we recommend keeping both the lyophilized powder and the reconstituted solution protected from light, on top of our standard storage temperatures for this product. Our general storage guidance for GHK-Cu already reflects this: -20°C for the lyophilized powder, 2 to 8°C after reconstitution, both out of direct light, with no repeated freeze-thaw cycles once reconstituted. Beyond light and air exposure, no published stability study isolates the copper component specifically as a variable for GHK-Cu, so the added light-protection emphasis is a precaution based on general copper(II) chemistry, not a GHK-Cu-specific study finding. In practice this means the same handling routine as our other lyophilized peptides, with more attention paid to keeping the vial out of light.

Question 20

Why does my GHK-Cu vial look nearly empty, is that a sign the product is missing or defective?

Accepted Answer

This is expected, not a defect. Our GHK-Cu vials contain only pure lyophilized peptide (50 mg or 100 mg), with no bulking agent like mannitol, so once the water is freeze-dried out, a few milligrams can look like a faint film, a small fleck, or a thin dusting on the glass rather than a powder mound. You can't judge the real amount by eye: it's the assayed content value on that batch's certificate of analysis, commissioned by the manufacturer (mostly Janoshik) and listed on our /coa page, for example 91.34 mg for one of our 100 mg Blue Cap batches. Match your vial's cap color and dosage to its CoA, not to how much you can see.

Question 21

How long does unopened, lyophilized GHK-Cu powder stay stable before it is ever reconstituted, and does it need to be refrigerated?

Accepted Answer

Sealed lyophilized powder is far more stable than the reconstituted solution, which is what makes shipping it practical: at typical transit temperatures the freeze-dried peptide tolerates the days to weeks a parcel is in transit without meaningful degradation. Once it arrives, our standing storage guidance for this product is -20°C, kept dark and dry, which gives the longest shelf life. A standard fridge (2-8°C) is an acceptable middle ground if freezer space isn't available, though it won't hold up quite as long. Because GHK-Cu's copper center is redox-active, keeping the sealed vial out of light matters more here than for a peptide with no metal center. This is separate from, and more forgiving than, the roughly 4-week window for the solution once reconstituted.

Question 22

How does GHK-Cu compare to other copper-binding peptides like AHK-Cu or copper tripeptide-1 (Matrixyl)?

Accepted Answer

Copper Tripeptide-1 isn't a separate peptide to compare against: it's the INCI cosmetic-ingredient name for GHK-Cu itself (see our note above on cosmetic-grade versus research-grade GHK-Cu), so anything labeled that way is the same glycyl-L-histidyl-L-lysine copper(II) complex we sell. Matrixyl is a different trademarked cosmetic peptide with no copper in it, not another name for copper tripeptide-1, worth flagging since the two get used interchangeably online. AHK-Cu is the genuinely distinct one: it swaps GHK-Cu's glycine for an alanine (alanyl-L-histidyl-L-lysine copper(II)), a synthetic analog developed mainly for topical cosmetic formulations, with a far smaller published research base than GHK-Cu, which occurs naturally in human plasma. Our catalogue and everything in this FAQ is specifically about GHK-Cu, not AHK-Cu or any other copper-tripeptide variant.

Question 23

Has GHK-Cu been studied specifically for hair growth or hair loss, and what did that research actually show?

Accepted Answer

None of the six studies behind our /research/ghk-cu page tested hair growth or hair loss; they are skin and wound-healing models. A separate literature does exist on copper-peptide complexes and hair, including cultured human hair-follicle (organ-culture) work reporting that copper-peptide treatment prolonged the follicle's active growth phase compared with untreated controls, and small human studies on multi-ingredient scalp formulations containing a copper peptide reporting improved hair density. Those formulations are complexes with several active ingredients, not a standalone reconstituted peptide like our vial, so they describe a different product, not ours. See /research/ghk-cu and PubMed for primary sources; this is not a result to expect from our vial.

Question 24

Do people combine GHK-Cu with BPC-157 or TB-500, and is that different from buying GLOW or KLOW instead?

Accepted Answer

No published study has tested GHK-Cu combined with BPC-157 or TB-500, the same gap our GLOW FAQ already discloses. GLOW (GHK-Cu, BPC-157, TB-500) and KLOW (those three plus KPV) put separately studied peptides in one vial, but the fixed combinations have never been tested as a unit, only their individual ingredients have. Each peptide's proposed mechanism, collagen and growth-factor signaling for GHK-Cu, angiogenesis and repair signaling for BPC-157 and TB-500, is complementary in theory, not evidence of a combined effect. GLOW or KLOW gives one pre-mixed vial instead of self-combining separate ones; see /research/ghk-cu, /research/bpc-157 and /research/tb-500 for what each was studied for. None of this is a stacking or dosing protocol for a person.

Question 25

Does the copper in GHK-Cu pose an overdose or toxicity risk, or is that only a concern for specific conditions like Wilson's disease?

Accepted Answer

Copper handling in the body is dose- and context-dependent, and Wilson's disease is a separate, genetic disorder of copper metabolism (a mutated ATP7B transporter) that causes toxic copper accumulation regardless of intake, not something caused by an outside compound like GHK-Cu. None of the cell-culture, ex vivo skin, or animal studies behind our /research/ghk-cu page reported systemic copper toxicity at the concentrations or doses tested, and no completed human safety trial has checked for it directly. This is general background, not medical guidance: it says nothing about any individual's copper-metabolism status, and our product is sold strictly for laboratory research use, not for evaluation or use in a person with any medical condition.

Question 26

Is the published GHK-Cu research based on topical application, injection, or both, and does the route change how much evidence backs it?

Accepted Answer

The published evidence splits by route. Nearly all the human-relevant data, the original collagen-synthesis work in cultured skin fibroblasts and the ex vivo cadaver-skin penetration study, used topical or cell-culture exposure. Most of the regenerative/wound-healing literature (mouse scald-wound, mouse emphysema, rat irradiated-flap) used animal models given the peptide topically or by intraperitoneal injection, a route used in research animals, not people. No human injection study of GHK-Cu has been published, and the one registered human trial (a Phase 2 topical wound-healing study) uses a topical route, not injection. This describes what the cited studies did, not instructions for how anyone should use, apply, or administer anything; see /research/ghk-cu for the full study list.

GHK-Cu

What is GHK-Cu

How it works

Often studied alongside

Documentation

Storage and stability

Frequently Asked Questions

Technical data sheet

Frequently bought together

KPV

BPC-157

KLOW

GLOW

Bacteriostatic Water

Lab Measuring Syringe + Prep Wipes Set (1 mL 31G)

Graduated Measuring Syringe 1 mL 31G x 6 mm

Alcohol Prep Pads 30 x 65 mm

Peptide Storage Box (10 Compartments)

Peptide Vial Case 30 Slots